ArticleCurrent urology2025
Patients with frailty, benign prostatic hyperplasia and indwelling bladder catheter: What are the 1-year outcomes after Rezūm therapy?
Article in Current urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comparative performance of mFI-5 and mFI-11 thresholds in predicting outcomes after holmium laser enucleation of the prostate.BJUI compass · 2026Article
- Small procedures, big complications.World journal of urology · 2026Article
- Water vapor thermotherapy and high-grade Clavien-Dindo complications: retrospective analysis of 10 cases.World journal of urology · 2026Article
- Re: Patients with frailty, benign prostatic hyperplasia and indwelling bladder catheter: What are the 1-year outcomes after Rezūm therapy?Current urology · 2026Article
- Urodynamic de-obstruction and symptom improvement after thulium laser vaporization (ThuVAP): evidence from a prospective paired study.The Canadian journal of urology · 2026Article
- Modified water vapor thermal therapy for large-volume benign prostatic hyperplasia.BMC urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rezūm therapy, a minimally invasive surgical procedure for benign prostatic hyperplasia (BPH), was very recently developed. Its characteristics and safety profile render its use in patients with multiple comorbidities attractive. In this study, we evaluated the outcomes of Rezūm therapy in patients with frailty, BPH, and an indwelling catheter. Methods: This single-center prospective study involved consecutive patients with frailty who underwent Rezūm therapy from June 2022 to December 2023. Patients with a prostate volume of 30-150 cm Results: Seventy patients were included: catheter removal was successful in 66 of these patients (94%), all of whom completed 1 year of follow-up without recatheterization. Statistically significant ( Conclusions: Rezūm therapy was effectively and safely performed in patients with frailty, BPH, and an indwelling catheter. Further large comparative studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.